On December 19, 2023, INTCO Medical issued the "Progress Announcement on Participating in the Investment in Qilu Qianhai (Qingdao) Venture Capital ** Partnership (Limited Partnership)", indicating that Shandong Yingke Medical Products, a wholly-owned subsidiary of Yingqi, subscribed for the share of Qilu Qianhai (Qingdao) Venture Capital ** Partnership (Limited Partnership) with its own funds, and subscribed for a capital contribution of 20,000 yuan. Shandong Yingke and the company signed the "Agreement on the Transfer of Capital Contribution Shares of Qilu Qianhai (Qingdao) Venture Capital ** Partnership (Limited Partnership)", and the share of 80 million yuan was 8,610The consideration of 130,000 yuan was transferred to INTCO Medical. The company's subscribed share in the ** was changed from 200 million yuan to 80 million yuan. The capital contributions of the partners include Qianhai Ark (Qingdao) Venture Capital**Management Partnership (Limited Partnership), Qingdao West Coast Financial Development***, Shandong Province New Kinetic Energy **Management***, etc. The company said that the change will not adversely affect the company's financial condition and results of operations.
INTCO Medical Technology Co., Ltd. was listed on the Growth Enterprise Market of the Shenzhen Stock Exchange on July 21, 2017, and its main business is medical care products. In the national economic industry, it belongs to the manufacturing industry and the rubber and plastic products industry. In terms of Shenwan industry classification, it belongs to the major category of medicine and biology and the subcategory of medical devices. As of October 25, 2023, the actual controller of the company is Liu **.
As of December 19, 2023**, the company's share price is 2276 yuan shares, with a circulating market value of 1158.2 billion yuan.
Announcement**: Disclaimer: This article is written by the robot, jointly incubated by Pencil Road and Hanxin Society, and the main data is provided by Hanguang Suwen. The content and data in this article are for reference only and do not constitute investment advice.